What PolyVation does

PolyVation BV is a privately held, ISO 13485-certified and EU/FDA GMP-compliant specialty polymer manufacturer founded in 1996 as a spin-off from the Polymer Laboratories of the University of Groningen and the related University Medical Center (UMCG). The company designs, develops, scales up and manufactures custom synthetic polymers for advanced biomedical and pharmaceutical applications, serving medical-device, pharmaceutical, and regenerative-medicine customers from pre-clinical through commercial supply stages worldwide. Its portfolio spans bioabsorbable polymer families (polyesters, polyetheresters, polyorthoesters, polyurethanes) and biostable families (vinyl pyrrolidone and acrylate copolymers), anchored by five patented branded technology platforms: Aegimer™ (tunable VP-maleate copolymers for medical-device coatings and skin barriers), PolyActive™/PEOT-PBT (thermoplastic elastomers for 3D printing and tissue engineering), Platimer™ (high-performance biomedical PLA for load-bearing devices), Orthomer™ (surface-eroding polyorthoesters for drug and gene delivery), and SynBiosys™ multi-block copolymers commercialized via the InnoCore Pharmaceuticals venture, with InGell Labs extending into injectable thermogel/biogel depots.

PolyVation runs an enterprise B2B custom manufacturing and R&D services model, with quote-based pricing on development projects and gram-to-multi-kilogram GMP manufacturing supply, supported by in-house analytical, regulatory-filing and Design History File support. Operations are concentrated at Campus Groningen (Kadijk 7D and the adjacent Kadijk 5 building inaugurated September 2025, together ~6,000 sqm), supplemented by a 1,500 sqm InnoCore formulation-development facility at the Healthy Aging Campus. The company employs approximately 85 staff, integrates with the InnoCore Pharmaceuticals and InGell Labs drug-delivery ventures, holds one of the longest-running ISO 13485 certifications in biomaterials (since 2010, last renewed November 2024 by DEKRA with zero findings), and maintains strategic collaborations with undisclosed global materials and coating-technology partners plus a research alliance with UMCG Biomedical Engineering.

Name

PolyVation

Legal name

PolyVation BV

Website

https://polyvation.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

51–100 employees

Short description

PolyVation is an ISO 13485-certified, GMP-compliant specialty polymer CDMO founded in 1996 in Groningen, Netherlands, providing custom synthesis, development, and GMP manufacturing of bioresorbable and biostable polymers for medical-device and pharmaceutical customers worldwide.

Ownership category

akta.pro rank

Product category

Specialty Polymer Manufacturing

NAICS

Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing (3252), Resin and Synthetic Rubber Manufacturing (32521)

SIC

Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821)

akta.pro primary industry

Biodegradable Polymers & Resins (PLA, PHA, PBS, PBAT) (IMAEAOAA)

akta.pro secondary industry

Polyurethanes (MDI/TDI, Polyols, PU Systems) (IMAEADAH)

Keywords

• Custom polymer synthesis
• GMP polymer manufacturing
• Bioresorbable polymers
• Medical device coatings
• Controlled release polymers

Headquarters

HQ city

Groningen

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Custom Polymer Manufacturing: Custom synthesis and manufacturing of specified polymers or reactive functional molecules at gram to multi-kilogram batch scale under ISO/GMP quality standards. Revenue from commercial manufacturing of specialty polymers for biomedical and pharmaceutical applications.
2. R&D Services: Polymer development, process development, scale-up services, regulatory filing support, and analysis services. Revenue from consulting, development work, and technical services supporting customers through (pre)clinical milestones.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

PolyVation is an ISO 13485 certified and GMP compliant manufacturer specializing in customized synthesis, development and manufacturing of specialty polymers for advanced biomedical and pharmaceutical applications. The company produces proprietary branded polymer product families (Aegimer™, PolyActive™, Platimer™, Orthomer™, SynBiosys™, InGell) and provides custom polymer synthesis and manufacturing at gram to multi-kilogram batch scale, serving medical device and pharmaceutical companies worldwide. Services span process development, scale-up, regulatory filing support, analytical testing, and commercial GMP supply.

Product overview

PolyVation provides polymer development, custom synthesis, scale-up, and GMP manufacturing services for advanced biomedical and pharmaceutical product applications. Their portfolio includes multiple branded polymer products — Aegimer™ (vinyl pyrrolidone maleate copolymers for medical device coatings), Platimer™ (high-performance lactide polymers for load-bearing devices), Orthomer™ (polyorthoesters for drug delivery), SynBiosys™ (multi-block copolymers for controlled release via InnoCore Pharmaceuticals), and InGell (injectable thermogel/biogel polymers) — alongside enabling technology categories for controlled release, PLGA-PEG-PLGA, PEOT/PBT, and lactide polymers. These are complemented by custom manufacturing and R&D service offerings. The company operates from Groningen, The Netherlands (founded 1996 as University of Groningen spin-off) with approximately 85 employees including InnoCore and InGell subsidiaries.

Differentiator

Problem solved

Functional benefit

Brands

• Aegimer™: Patented family of novel vinyl pyrrolidone copolymers with modified maleates for super-lubricious medical device coatings and antimicrobial skin care products.
• Platimer™
• Orthomer™
• PolyActive™
• PLGA-PEG-PLGA

Products and services

• Aegimer™ Vinyl Pyrrolidone Maleate Copolymers Patented family of vinyl pyrrolidone maleate copolymers with tuneable hydrophilic/hydrophobic balance, used for super-lubricious medical device coatings (catheters, IOL cartridges), antimicrobial skin care, and echogenic medical device coatings. Can be crosslinked to form hydrogel layers or stand-alone gel depots. Patents granted in key countries worldwide including the USA.
• Platimer™ High Performance Biomedical PLA High-performance biomedical PLA (Poly Lactic Acid) combining superior mechanical properties with biocompatible degradation. Platimer 232 has IV of ~3.2 dL/g and fully degrades in approximately 24 months; Platimer 228 with IV of ~2.8 dL/g optimized for 3D printing of scaffolds. Degradation rate adjustable without compromising mechanical properties. Available in granulate and powder forms.
• Orthomer™ Polyorthoesters Bioresorbable polyorthoester (co)polymers for controlled drug and gene delivery applications. Degrades predominantly through surface erosion (unlike bulk-eroding PLA/PLGA). Stable at alkaline/neutral conditions, rapidly hydrolyze at acidic conditions with controllable rates. Glass transition temperatures of 80-100°C available (vs 50-60°C for PLA/PLGA), useful for controlling release of smaller molecular weight drugs.
• PolyActive™ PEOT/PBT Multi-block Copolymers PEOT/PBT multi-block copolymers (thermoplastic elastomers) that are bioresorbable with phase-separated morphology combining hydrophilic and hydrophobic segments. Tunable mechanical properties, highly suitable for 3D printing with low melting viscosity and good post-cooling mechanical properties. Ideal for tissue engineering scaffolds and membranes with selective permeability.
• SynBiosys™ Multi-block Copolymers Patented family of bioresorbable multi-block copolymers for medical and pharmaceutical controlled release systems. Focus on medical device coatings, microspheres, and injectable solid implants. Commercialized through InnoCore Pharmaceuticals subsidiary.
• InGell Injectable Polymer Systems Unique injectable liquid bioresorbable polymer systems that form soft depots after injection in vivo (thermogels and biogels). Pharmaceutical product development offered through InGell Labs operating with InnoCore Pharmaceuticals.
• PLGA-PEG-PLGA Thermoresponsive Triblock Copolymers Amphiphilic thermoresponsive triblock copolymers that form flower-like micelles in water at low temperature. Upon injection at body temperature, micellar solution transforms into hydrogel depot. Enables injectable gel drug delivery formulations with controlled release periods from days to weeks.
• Custom Polymer Manufacturing Service Custom synthesis and manufacturing of specified polymers or reactive functional molecules from gram-scale to multi-kilogram batch scale, with GMP and ISO 13485 compliance. Covers bioabsorbable polymers (polyesters, polyetheresters, polyorthoesters, polyurethanes) and biostable polymers (vinyl pyrrolidone, acrylate, vinyl alcohol graft copolymers). Maximum reactor capacity of 350 L.
• Polymer Research & Development Services Polymer development services including new polymer development, modification of existing polymers, library of polymers, R&D materials supply, prototyping support, problem solving, analysis, and regulatory filing support. Includes Design History File documentation guided by design control procedure for (pre)clinical milestones, plus analytical and physical-chemical biocompatibility testing in-house.

Quantifiable outcome

• Platimer™ 232 fully degrades in approximately 24 months
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Pharma NL InitiativeminorStrategic or Co-development Partner · 19 November 2021Pharma NL initiative aims to build a flourishing pharma industry in the Netherlands for better secured access to medicine. PolyVation supports this initiative as worldwide renowned customized developer and maker of polymers for innovative medicine - including controlled release excipients and drug molecule backbones.
• InnoCore PharmaceuticalscoreStrategic or Co-development PartnerInnoCore Pharmaceuticals is a polymer technology subsidiary and partner of PolyVation. Capitalizes patented family of bioresorbable multi-block copolymers (SynBiosys™) for medical and pharmaceutical controlled release systems. Focus on medical device coatings, microspheres, and injectable solid implants. PolyVation handles polymer scale-up and GMP supply for InnoCore products.
• InGell LabscoreStrategic or Co-development PartnerInGell Labs is a polymer technology subsidiary of PolyVation. Develops unique injectable liquid bioresorbable polymer systems (InGell polymers) that form soft depots after injection in vivo (thermogels and biogels). InnoCore Pharmaceuticals operates integrated with InGell Labs for pharmaceutical product development.
• Bether EncapsulatesminorStrategic or Co-development PartnerCollaborative partnership with Bether Encapsulates and UMCG research department of Biomedical Engineering (prof. dr. Patrick van Rijn) to develop polymer coating technology for implants containing stabilized gas bubbles loaded with antibiotics. Enables ultrasound-triggered ON/OFF antibiotic release.
• UMCG (University Medical Center Groningen) - Biomedical Engineering DepartmentminorStrategic or Co-development PartnerResearch collaboration with UMCG's Biomedical Engineering department, led by prof. dr. Patrick van Rijn, for developing triggered release technology using polymer coatings with stabilized gas bubbles for antibiotic delivery via medical ultrasound.
• Global Materials Company (Polyorthoesters Partnership)coreStrategic or Co-development PartnerExclusive business development partnership with one of the world's leading materials companies to accelerate product development and advance product opportunities using polyorthoesters in the pharmaceutical space. The relationship is not yet public.
• Coating Technology CompanycoreStrategic or Co-development PartnerStrategic collaboration established with one of the world's leading coating technology and application companies for Aegimer™ PVP-Maleate copolymers. Enables best-in-class super-lubricious medical device coatings for applications including catheters and IOL cartridges.

Scale indicators8 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• Poly-Med (Smith+Nephew): Poly-Med (acquired by Smith+Nephew) is one of the closest direct comparables: a specialty bioresorbable polymer manufacturer serving medical-device and pharmaceutical customers with custom synthesis and GMP manufacturing of lactide/glycolide and other absorbable polymers.
• Secant Group (Telfa): Secant Group develops custom bioresorbable and biocompatible polymers, textile structures, and implantable components for medical-device customers, competing head-to-head with PolyVation in custom polymer development and scale-up.
• Foster Corporation: Foster Corporation is a custom compounder and manufacturer of medical-grade polymers (including bioresorbable and radiopaque compounds) for medical-device OEMs — a comparable niche custom polymer CDMO serving similar medical-device customers.

Broad incumbents

• Evonik Health Care (Resomer): Evonik's Health Care division sells the Resomer® portfolio of bioresorbable PLLA, PDLLA, PLGA, and PCL polymers for medical devices and drug delivery — overlapping directly with PolyVation's PolyActive, Platimer, and SynBiosys platforms but at significantly greater scale.
• Corbion: Corbion is a global leader in PLA bioplastics and lactic-acid derivatives, with biomedical-grade lactide polymers (PURAC) used in medical devices and drug delivery, making it a scaled incumbent peer to PolyVation's Platimer™ PLA line.
• Ashland Specialty Ingredients / Pharmaceuticals: Ashland supplies pharmaceutical specialty polymers and excipients (including PVP/VA copolymers similar to Aegimer™) used in oral solid dose, coatings, and controlled-release applications, competing for pharma formulation customers served by PolyVation.
• BASF Pharma Solutions: BASF Pharma Solutions offers a broad portfolio of excipients, polymers, and drug-delivery enablers (including PVP, PLA/PLGA, and specialty copolymers) to global pharma customers — a broad incumbent alternative source to PolyVation's specialty polymers.
• DSM Biomedical (dsm-firmenich): DSM Biomedical (now part of dsm-firmenich) supplies biomaterials, including bioresorbable polymers, hydrogels, and coatings for medical devices and drug delivery — directly comparable to PolyVation's portfolio and a typical incumbent alternative for the same medical-device customers.
• Croda Life Sciences: Croda Life Sciences supplies specialty excipients, polymers, and drug-delivery systems to pharmaceutical and medical-device customers globally, including polymer-based controlled-release and skin-care technologies that overlap with PolyVation's controlled-release and Aegimer™ platforms.
• Lubrizol Life Science (Estane): Lubrizol Life Sciences (Berkshire Hathaway) provides engineered polymers, including thermoplastic polyurethanes (Estane®) and specialty biomaterials for medical devices, directly comparable to PolyVation's polyurethane and biostable offerings for implants and coatings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PolyVation